Feedback / Questions
MEDI6012 - AstraZeneca
AstraZeneca: Q3 FY 2016 Results
(AstraZeneca)
-
Nov 12, 2016 -
Anticipated top-line results from P2a (NCT02601560) trial in adults with stable CAD and low HDL in H2 2016
Anticipated P2a data
•
Dyslipidemia
https://www.astrazeneca.com/content/dam/az/press-releases/2016/Q3_2016_Clinical_trials_appendix.pdf
Nov 12, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious